Astec Lifesciences Limited (ASTEC) AI Stock Analysis

• Market Cap: ₹14.25B
• Dividend Yield: N/A
• Average Volume (3M): 412.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: 1.54%
• EPS Growth: -8.04%
• Country: IN
• Employees: 606
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -11.00
• Shares Outstanding: 22,281,660
• 10 Day Avg. Volume: 47,730
• 30 Day Avg. Volume: 412,490
• PEG Ratio: -0.06
• Price to Book (P/B): 6.10
• Price to Sales (P/S): 3.76
• P/FCF Ratio: -47.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ₹829.00 ▲(17.84% Upside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenue, negative margins, and liquidity issues. While technical analysis shows positive momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.

Positive Factors

R&D Capabilities

Astec's focus on R&D enhances its ability to innovate, supporting long-term growth through new product development and market expansion.

International Market Presence

Astec's international reach and partnerships bolster its competitive position, providing diversified revenue streams and reducing dependency on domestic markets.

Product Diversity

A diverse product portfolio in agrochemicals and pharmaceuticals enhances resilience against market fluctuations and supports steady revenue generation.

Negative Factors

Declining Revenue

Declining revenue indicates potential market challenges or operational inefficiencies, threatening long-term financial stability and growth prospects.

Negative Margins

Sustained negative margins reflect cost management issues and can hinder reinvestment in growth initiatives, affecting future profitability.

High Leverage

Increased leverage raises financial risk, limiting flexibility and potentially impacting the company's ability to invest in growth or weather downturns.

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec Lifesciences Limited (ASTEC) is a leading manufacturer and supplier of agrochemicals and pharmaceutical intermediates based in India. The company operates primarily in the agrochemical sector, focusing on the production of herbicides, fungicides, insecticides, and other crop protection products. Additionally, ASTEC is involved in the development of pharmaceutical intermediates and specialty chemicals, catering to both domestic and international markets. Leveraging its strong research and development capabilities, the company aims to provide innovative solutions for sustainable agriculture and healthcare.

How the Company Makes Money

Astec Lifesciences generates revenue primarily through the sale of its agrochemical products and pharmaceutical intermediates. The company's revenue model is built on manufacturing and distributing a diverse range of crop protection chemicals, which are sold to agricultural businesses and distributors. Key revenue streams include the sale of branded and generic agrochemicals, contract manufacturing services for third parties, and the export of products to international markets. Significant partnerships with global agricultural firms enhance its market reach and contribute to earnings through collaborative projects and joint ventures. Additionally, the company's focus on research and development allows it to introduce new products, thereby expanding its market presence and driving revenue growth.

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.

Income Statement

The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.

Balance Sheet

The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.03B	3.81B	4.58B	6.28B	6.77B	5.55B
Gross Profit	973.81M	-685.16M	1.33B	2.27B	2.86B	2.10B
EBITDA	-271.65M	-662.07M	-2.69M	893.14M	1.65B	1.19B
Net Income	-1.28B	-1.35B	-469.30M	255.65M	898.59M	650.49M
Balance Sheet
Total Assets	0.00	8.81B	9.75B	9.79B	8.97B	6.78B
Cash, Cash Equivalents and Short-Term Investments	5.75M	8.55M	16.47M	27.54M	33.44M	15.42M
Total Debt	0.00	5.55B	4.94B	3.41B	2.79B	1.87B
Total Liabilities	-2.35B	6.46B	6.05B	5.60B	5.00B	3.68B
Stockholders Equity	2.35B	2.35B	3.69B	4.19B	3.96B	3.09B
Cash Flow
Free Cash Flow	0.00	-302.20M	-1.25B	-426.03M	-803.74M	-1.11B
Operating Cash Flow	0.00	-83.99M	102.21M	746.56M	236.04M	-81.62M
Investing Cash Flow	0.00	-152.30M	-1.35B	-1.13B	-1.04B	-731.10M
Financing Cash Flow	0.00	237.33M	1.25B	377.70M	804.77M	813.36M

Astec Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 703.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 703.5 is below the 20-day moving average (MA) of 705.08, below the 50-day MA of 719.31, and below the 200-day MA of 770.72, indicating a bearish trend. The MACD of -18.57 indicates Positive momentum. The RSI at 30.41 is Neutral, neither overbought nor oversold. The STOCH value of 6.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PUNJABCHEM	64 Neutral	₹13.49B	25.80	―	0.24%	10.70%	32.65%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹23.02B	19.87	―	0.97%	5.74%	16.06%
IGPL	59 Neutral	₹11.73B	36.09	―	2.59%	-10.71%	-40.89%
ASTEC	52 Neutral	₹14.25B	-11.29	―	―	1.54%	-8.04%
UNIENTER	49 Neutral	₹9.88B	52.01	―	0.34%	―	―
HERANBA	44 Neutral	₹8.89B	-18.90	―	0.39%	―	―

Astec Lifesciences Limited Corporate Events

Astec LifeSciences Announces Senior Management Change

Astec LifeSciences Limited, a company involved in the life sciences sector, has announced the resignation of Mr. Vivek Ramchandra Thorat from his position as Associate Vice President – Operations, effective from the close of working hours on October 24, 2025. This change in senior management is due to Mr. Thorat’s decision to pursue opportunities outside the company. The company has accepted his resignation and relieved him of his duties.